btlines

PTG GPW Periodic report · PAP Biznes

PolTREG SA (PTG) · Q1 2026 results

Share price: 19.15 zł · 2026-11-10

Results Q1 2026 vs Q1 2025 · year over year · published 11 May 2026 and 14 May 2025

Net loss widened year on year. The report's language is unchanged.

Only a basic analysis is available for this company at the moment.

1 · Numbers

Loss widened

Net income vs Q1 2025

Net income -6.8M vs -5.5M

Revenue +69328.0%

2 · How the report reads

Unchanged

Language tone vs last period

Report language: upbeat for a company report — about as upbeat as in Q1 2025.

Weak signal: formal report language, not a call.

3 · What stood out

Fading

PTG signed an agreement with the Medical Research Agency to implement and co-finance a research and development project.

Official channels

The company's own website and social media accounts.

Read between the lines

No major shifts flagged this period.

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.

Report language Upbeat (was upbeat)

Upbeat for a company report — about as upbeat as in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.

Sentences that drove the tone
“The concluded agreement assumes that expenditures for the future development of the project by Immuthera will be provided by local institutions specialized in financing the development of innovative medicinal products.”
“Liabilities Cumulative loss Equity Liabilities”

Full figures

PLN · PAP Biznes report (2026-05-11)

Metric Q1 2026 Q1 2025 Change
Revenue 69.4M 100.0K +69328.0%
Operating income -6.5M -5.7M Loss widened
Net income -6.8M -5.5M Loss widened
EPS -1.45 -1.17 Loss widened
P/E 12-mo loss 12-mo loss —

Topics

Topics are drawn from the full report text, not management commentary.

Most discussed now

  • The objective of the Horizon 2020 project was to prepare the registration phase and the Phase III clinical trial of the Treg lymphocyte…
  • In certain cases, the agreement also grants NCBiR the right to terminate it with immediate effect.
  • The Company's strategy assumes the development of innovative therapies for autoimmune diseases using regulatory T cells (Treg).
  • Fading The acquired license enables the alignment of the product portfolio to every stage of type I diabetes development as well as its expansion…
  • The planned research tasks include the preparation and conduct of a phase II clinical trial.

Faded since Q1 2025

  • Fading The Company's strategy involves developing innovative therapies for autoimmune diseases using regulatory T cells (Treg).

Latest announcements

Official filings, newest first.

Similar companies

Healthcare · Biotechnology
All Healthcare companies →